The anti-allergic activity of Benoxaprofen [2-(4-chlorophenyl)-alpha-methyl-5-benzoxazole acetic acid]--a lipoxygenase inhibitor.
Benoxaprofen [2-(4-chlorophenyl)-alpha-methyl-5-benzoxazole acetic acid], a novel anti-inflammatory compound, is also an orally-active anti-allergic compound in animals. It reduced the anaphylactic release of mediators, particularly slow-reacting substance of anaphylaxis (SRS-A), from both in vitro and in vivo animal models. Benoxaprofen marginally antagonized the activity of histamine on the guinea pig ileum, but not of SRS-A, at concentrations which inhibited the release of SRS-A.
D000707:Anaphylaxis / Q000276:immunology / Q000378:metabolism; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001583:Benzoxazoles / Q000494:pharmacology* / Q000627:therapeutic use; D001986:Bronchial Spasm / Q000188:drug therapy; D004306:Dose-Response Relationship, Immunologic; D006168:Guinea Pigs; D006633:Histamine Antagonists / Q000494:pharmacology; D006636:Histamine Release / Q000187:drug effects; D006801:Humans; D016859:Lipoxygenase Inhibitors; D008168:Lung / Q000378:metabolism; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology; D011422:Propionates / Q000494:pharmacology* / Q000627:therapeutic use; D051381:Rats; D011919:Rats, Inbred Strains; D013189:SRS-A / Q000037:antagonists & inhibitors / Q000378:metabolism
D000893:Anti-Inflammatory Agents; D001583:Benzoxazoles; D006633:Histamine Antagonists; D016859:Lipoxygenase Inhibitors; D010726:Phosphodiesterase Inhibitors; D011422:Propionates; D013189:SRS-A; C011677:benoxaprofen